Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
Abstract Number and Title: #8304, “Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer (NSCLC)”
Poster Session Title: Phase I-III Trials in
Session Date and Time:
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17, Poster Board Number: #18
Permanent Abstract Number: CT224
About DV281
DV281 is
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact
Vice President, Investor Relations & Corporate Communications
510-665-7269
Source: Dynavax Technologies Corporation